Nobel Medicine Prize Goes To 3 Scientists For Research Into Brain Activity

TL;DR

Prime Big Deal Days · Oct 6–7Offer from Amazon

Get workout gear delivered free — and shop member deals

• Fast, free delivery on millions of items
• Access to Prime Big Deal Days deals on October 6–7
• Prime Video, Amazon Music and more included

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

The Nobel Prize in medicine was awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for research underpinning optogenetics, a method that uses light to control nerve cells. The technique is widely used in neuroscience research; its main role remains experimental, although related approaches are being studied for potential treatments.

The Nobel Prize in medicine was awarded Monday to Karl Deisseroth, Peter Hegemann and Georg Nagel for research that made optogenetics possible, a technique that uses light to control nerve-cell activity. The Nobel Assembly said the tool is now used in laboratories around the world to investigate how the brain works.

The research centers on light-gated ion channels, proteins that respond to light by allowing charged particles to pass through a cell membrane and trigger an electrical signal. Hegemann studied how a single-celled green alga moves toward light. He and Nagel identified a protein that opens a channel when illuminated with blue light, making cells containing it responsive to light.

Deisseroth used the gene that controls the protein to develop a way to make nerve cells responsive to light. He also developed tiny optical fibers to deliver light to modified cells in the brains of living mice. Researchers can use the method to switch particular neurons or circuits on or off and observe the effects, allowing experiments that would be difficult to conduct with less targeted tools.

Deisseroth, a Howard Hughes Medical Institute investigator and Stanford University professor, is based in California. Hegemann is at Humboldt University in Berlin, and Nagel most recently worked at the University of Würzburg, the Nobel Assembly said. The prize carries 12 million Swedish kronor, about $1.2 million, to be shared by the three laureates.

A Tool for Testing Brain Circuits

Optogenetics gives researchers a way to test whether activity in a particular group of nerve cells contributes to a behavior or brain process. Rather than only recording activity and looking for associations, scientists can manipulate selected cells with light and study what changes. That ability has helped researchers investigate neural pathways linked to behavior and examine how brain circuits may be disrupted in disease.

The Nobel Assembly said the work has implications for conditions including blindness, depression, addiction and dementia. These are research implications, not evidence that optogenetics is an established treatment for those conditions. Deisseroth described the method as using light not merely to observe, but to control activity with precision. The distinction matters because findings from laboratory experiments can guide future work, but do not by themselves show that a treatment is safe or effective for patients.

Some researchers are pursuing possible clinical applications. Deisseroth said a direct optogenetics approach is being used to test a treatment for a genetic form of vision loss, retinitis pigmentosa. The report does not provide trial details or results, so the status and effectiveness of that approach cannot be assessed from the available information.

From Algal Protein to Neuroscience

The discovery developed across several stages. Hegemann’s work on green algae focused on how the organism detects and responds to light. He and Nagel identified a light-sensitive protein that could produce an electrical response in cells. The researchers’ findings made it possible to place the protein, or the gene controlling it, into other cells and make them light-responsive.

Deisseroth then adapted that biological mechanism for experiments involving nerve cells. The resulting technique became known as optogenetics, combining light control with genetic methods. According to the Nobel Assembly, the method opened a new era in neuroscience by allowing researchers to manipulate defined nerve cells and circuits in living brains.

Jeremy Berg, a University of Pittsburgh scientist who was at the U.S. National Institutes of Health in the early 2000s, recalled that the NIH funded Deisseroth’s proposal for optogenetics. Berg said the vision described then was “pretty much spot-on the way it played out,” and characterized the resulting tools as unusually precise ways to study brain function.

““People usually think about light as a way of collecting information to observe things. But this is the opposite of that. This is using light to control things, to make things happen, and to do it in a very precise way.””

— Karl Deisseroth, Stanford University and Howard Hughes Medical Institute

Clinical Uses Remain Under Study

The prize recognizes foundational research and a widely used laboratory technique; it does not establish optogenetics as a general medical treatment. The source report says the method is mostly used to study how specific neurons and circuits work. It mentions a test of an approach for retinitis pigmentosa, but gives no information about the study’s phase, participants, safety findings or outcomes.

It is also not clear from the announcement which clinical applications may eventually prove practical, or how long that would take. The Nobel Assembly and scientists quoted in the report describe research potential and implications, while the report provides no evidence that optogenetics has produced approved treatments for the listed conditions.

Nobel Week Continues in Stockholm

The medicine award opened Nobel week in Stockholm. The physics prize is scheduled for Tuesday, chemistry for Wednesday and literature for Thursday, followed by the peace prize on Friday. The Nobel Memorial Prize in Economic Sciences is due to be announced on Oct. 12.

For the laureates’ research, the next developments to watch are further studies using optogenetics to map brain circuits and any reported results from investigations into possible clinical applications. The announcement does not specify a timetable for those research milestones.

Key Questions

Who won the Nobel Prize in medicine?

Karl Deisseroth, Peter Hegemann and Georg Nagel shared the prize for research that enabled optogenetics.

What is optogenetics?

Optogenetics is a research technique that uses light-sensitive proteins and genetic methods to make selected cells respond to light. Researchers use it to control and study the activity of particular nerve cells and brain circuits.

Is optogenetics an established treatment?

The report describes optogenetics mainly as a laboratory research technique. It mentions a treatment approach for retinitis pigmentosa being tested, but provides no trial results or evidence of general clinical use.

How much is the prize worth?

The prize is 12 million Swedish kronor, approximately $1.2 million, shared among the three laureates.

Source: rss